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Aims: Nocturia, or waking up at night to void, is a highly prevalent and bothersome lower urinary tract symptom.
However, the applied treatmentmodalities do not improve symptoms in about half of the patients. The aimof this report is
to generate new ideas for future nocturia research, with special emphasis on the role of sleep physiology and sleep
disorders.Methods: The following is a report of the presentations and subsequent discussion of theNocturia ThinkTank
session at the annual meeting of the International Consultation on Incontinence Research Society (ICI-RS), which took
place in September 2015 in Bristol. General information about the organization of the ICI-RSmeeting can be found on the
website ‘‘www.ici-rs.org.’’ An overview of challenges within the existing evidence, future research ideas, and results of
research with regard to nocturia and sleep were presented. Results and conclusion: In order to optimize the
management of nocturia and nocturnal polyuria (NP), future research has to focus on the development of unambiguous
terminology regarding nocturia and NP, the role of renal function profiles and simplified frequency volume charts as
guidance of individualized therapy and the role of sleep disorders such as periodic limb movements during sleep and
habitual voiding as a response to awakening.Neurourol. Urodynam. 37:2048–2052, 2018. # 2016Wiley Periodicals, Inc.
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INTRODUCTION
Nocturia is defined as the need to wake up at least once per
night to void, with each void preceded and followed by sleep.
However, getting up twice or more is considered as a more
clinically relevant definition. In addition to a thorough history
and physical exam, analysis of a frequency volume chart (FVC)
allows one to identify the presence of nocturnal polyuria (NP),
global polyuria (GP), decreased nocturnal or global bladder
capacity (BC), or amixed etiology. A urine production exceeding
40ml/kg bodyweight during a 24hr period is defined as GP. The
definition of NP is based on the NP index (NPi), which is
calculated by dividing nocturnal urine production (NUP) by
24hr urine production. If 24 hr urine production remains
within normal limits, a NPi higher than 20% in the young and
greater than 33% (NPi33) in the old is considered as NP,with the
value of middle-age falling somewhere in between.1,2 Based on
the NPi33 definition, NP is present in up to 88% of patients with
nocturia and, therefore, the major contributing factor in
nocturia.3 The pathophysiological mechanisms underlying NP
are disorders in free water clearance, which is driven by the
antidiuretic hormone (ADH), and disorders in sodium clearance.
Both mechanisms can be distinguished using a renal function
profile (RFP). This is a 24hr urine collection, with the collection
of a urine sample every 3hr during 24hr, for analysis of diuresis
rate, osmolality, sodium, and creatinine concentrations. Renal
clearance of each substances can be calculated if serum levels of
these parameters are available (Usubsturine flow/Psubst). Such
a comprehensive assessmentmay be helpful to guide clinicians
toward a more individualized treatment: desmopressin in
patients with an increased free water clearance during
nighttime, timed diuretics in patients with an increased
nocturnal solute clearance, and anticholinergics in patients
with symptoms of an overactive bladder. This individualized
treatment, based on stratification of nocturia patients, may
result in higher treatment efficacy and lower side effects.4 If
this is confirmed in future research, a simplification of this RFP
will be necessary to use it in clinical practice.
CHALLENGES IN THE MANAGEMENT OF NOCTURIA
Although nocturia is one of the most common and
bothersome lower urinary tract symptoms (LUTS), the applied
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treatment modalities do not improve symptoms in about half
of the patients.5 Because the etiology of nocturia is multifacto-
rial, careful diagnosis of the underlying cause(s) and choice of
the correct treatment modalities is of utmost importance to
improve success rates.6 The cause of the relative lack of success
itself is multifactorial and may result from inadequate
diagnostic accuracy leading to a lack of cause-specific therapy,
leaving room for improvement through education and treat-
ment guidelines. Moreover, diagnoses and treatment of
concomitant causes such as obstructive sleep apnea (OSA),
primary sleeping disorders, hypertension, and diabetes may
often be overlooked. A better subtyping of nocturic patients and
a better screening for comorbidities such as sleep disorders,
may also influence results of pharmacological trials. For
example, the use of melatonin, which is a hormone with a
circadian rhythm, has some significant effects, but studies do
not support its use for nocturia, since clinically relevant effects
were not found.7
DIAGNOSING NOCTURNAL POLYURIA: CHALLENGING THE
CURRENT EVIDENCE
The current definition of NP is based on the observation that
the mean NPi was 14% in individuals<25 years old and 34% in
those over 65 years of age.2 Although this definition is not based
on normal distributions and not properly validated, a NPi33 is
often considered asNP in studies and clinical practice. However,
dozens of other definitions are used, either based on relative
measures where NUP production is set out against 24hr urine
production (NPi33, NPi> 35%), or based on absolute definitions
with urine production per kg or time unit (NUP>90ml/hr
(NUP90), NUP> 0.9ml/min, NUP> 6.4ml/kg), or based on
functional characteristics where urine output is linked to
bladder capacity.8 This wide variety of definitions makes it
difficult to compare results of diagnostic and therapeutic
studies.
In the Krimpen study, the NPi33 and NUP90 definitions were
compared in a male population between 50 and 78 years.
Regardless of symptoms, the prevalence of NP was 78% using
the NPi33 definition and 15% with the NUP90 definition.
Furthermore, NPi33 was observed in 92% of men with at least
two nocturia episodes but also in 70% of those without
nocturia. This suggests that the NPi33 definition has a limited
discriminative value for diagnosing NP as a cause of nocturia.
However, NUP90 was seen in 28% of men with nocturia and in
only 8% of those without nocturia.9,10
Despite the difficulties of defining NP, it seems that
the course of RFPs, which indicate the underlying
pathophysiologic mechanism of NP, is not influenced by
the chosen definition. Analysis of a FVC and RFP in 112 adults
showed that diuresis rate, free water clearance, and sodium
clearance have similar courses over 24 hr for both the
subgroup with and without NP based on five different
definitions (NPi>20–33% according to age, NPi> 33%,
NUP90, NUP> 10ml/kg, and nocturia index>1.5).11 Recom-
mendations for future research about terminology and
diagnosis of nocturia and NP are summarized in Table I.
COMPARISON BETWEEN NOCTURNAL-ONLY AND 24HR
FREQUENCY VOLUME CHARTS: RESULTS OF A PILOT STUDY
Despite the valuable objective data provided by 24 hr
FVCs, patients may have difficulty recording the volume
and timing of every void in a 24 hr period. Since duration of
a FVC is related to patient burden and noncompliance,
these patients may be more compliant in completing a
shorter nocturnal FVC.12 It is, however, unknown to what
extent a nocturnal FVC can be a substitute for a standard
24 hr FVC.
Methods
A retrospective review of FVCs submitted by men 18 years
with 1 nocturnal voids during the interval of 2009–2015 at a
Veterans Affairs-based urology clinic was carried out. Each FVC
was analyzed in three manners: the standard 24hr FVC, the
nocturnal-only FVC (only data from hours of sleep) and the
nocturnal FVC with availability of the 24hr urine volume.
Clinical variables derived from each FVC included 24hr urine
volume, nocturnal urine volume (NUV, including first morning
void), maximum voided volume (MVV), nocturnal maximum
voided volume (NMVV, greatest voided volume during sleep),
NPi, NUP (NUV/number of hours of sleep), nocturia index (Ni,
NUV/MVV), actual number of nocturnal voids (ANV), predicted
number of nocturnal voids (PNV, Ni-1), and nocturnal BC index
(NBCi, ANV-PNV). A NBCi>1.3 is considered a cutoff point
above which reduced nocturnal bladder capacity should be
investigated as a cause of nocturia.13 The etiologies (NP, GP,
decreased nocturnal/global BC) were not classified in a
mutually exclusive manner. The data were analyzed using
SPSS statistics version 21. MVV and NMVV (and their
corresponding NBCi’s) were analyzed using descriptive statis-
tics and compared using the Wilcoxon signed ranks test. The
sensitivity and specificity of the nocturnal FVCs in detecting
each etiology was determined in comparison to the standard
24hr FVC.
TABLE I. Recommendations for Future Research About Nocturia, Nocturnal Polyuria, and Sleep
Terminology and diagnosis
Determine methodologically well-founded definitions to define and quantify the grade of nocturia and nocturnal polyuria in men and women of all ages.
Explore the additive value of renal function profiles in randomized controlled trials evaluating different treatment options for nocturia (anti-diuretic
treatment, sodium restricted diet, timed diuretics). Utilization of renal function profiles before and after treatment allows correlation of
pathophysiology with success rate and side effects for each treatment option.
Define normal ranges for renal function profile parameters in healthy adults stratified for gender and age, and consequently suggesting cutoff values for
abnormal free water and sodium clearance.
Conduct prospective studies to assess if nocturnal-only frequency volume charts can provide clinicians with guidance regarding the etiology and
treatment of nocturia.
Better understanding of sleep, better understanding of nocturia?
Studies on bladder control and sensation on the brain level, using functional magnetic resonance imaging in combination with urodynamics, could be
helpful to distinguish convenience voids from nocturnal voids because of urinary urgency. Together with a comprehensive evaluation of nocturia,
assessment of sleep by using questionnaires, actigraphy, and polysomnography in nocturic patients of all ages is necessary to:
Identify sleep disorders as a cause or consequence of nocturia.
Evaluate the impact of periodic limb movements during sleep on nocturia and nocturnal polyuria in adults.
Determine which type of nocturia patient has a primary sleep pathology that needs treatment.
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Results
A total of 285 FVCs belonging to 170 unique male patients
with a mean age of 70 years and a mean (SD) number of
nocturnal voids of 2.9 (1.96) were reviewed. In 68% (193/285)
of cases, MVV and NMVV, and their respective NBCi’s were
equal. The mean (SD) MVV was 308 148.2 and the mean
NMVVwas 278 146. ThemeanNBCi based onMVV (NBCiMVV)
was 1.31.24 and the mean NBCi based on NMVV (NBCiNMVV)
was 1.01.33. There was a statistically significant difference
between MVV and NMVV (P< .001), as well as between
NBCiMVV and NBCiNMVV (P< .001). Table II compares nocturia
diagnoses gleaned from a standard FVC analysis with those
resulting from either the abbreviated nocturnal-only FVC or
nocturnal FVC with 24hr volume.
The nocturnal-only FVC demonstrated a 0% sensitivity in
detecting NPi33 and GP, but had 75% sensitivity in detecting
decreased nocturnal BC and 100% sensitivity in detecting
NUP90 and decreased global BC. The nocturnal FVC with 24hr
volume had 75% sensitivity in detecting decreased nocturnal
BC, but 100% sensitivity in detecting all other etiologies. Both
types of nocturnal FVCs demonstrated 100% specificity in
detecting all etiologies except decreased global BC, for which
they had 89% specificity.
Discussion
Despite the statistically significant difference between MVV
and NMVV (and their corresponding NBCi’s), NMVV proved to
be an acceptable surrogate for MVV. The data demonstrates
acceptable sensitivity and specificity from the nocturnal FVC
with 24hr volume in comparison to the standard FVC,while the
nocturnal-only FVCmay be of use to subset of patients inwhich
GP has been ruled out as an etiology for nocturia.
Conclusion and Future Research
Although nocturnal FVCs with 24hr volumemay not replace
standard 24hr FVCs, they are an alternative for patients who
may have difficulty completing a 24hr FVC. A nocturnal-only
FVC may be an alternative for nocturic patients who have had
GP ruled out as a possible etiology. Recommendations for future
research with nocturnal FVCs are summarized in Table I.
BETTER UNDERSTANDING OF SLEEP, BETTER UNDERSTANDING
OF NOCTURIA: CHALLENGING THE CURRENT EVIDENCE
Sleep is a specific behavior regulated by a homeostatic
process, which maintains the duration and intensity of sleep,
and a circadian rhythm that determines its timing. The
suprachiasmatic nucleus is the central circadian pacemaker
that drives daily fluctuations in physiologic functions such as
urine production ormicturition, and synchronize it to the 24hr-
day and normal sleep–wake schedules.14,15 The primary reason
for nighttime awaking in adults is nocturia, which shows a
decreasing quality of sleep with increasing number of nocturia
episodes.16 However, also sleep disorders such as OSA and
periodic limb movements during sleep (PLMS) are associated
with NP, nocturnal enuresis (NE), and nocturia.17–20
Periodic Limb Movements in Sleep and Dopaminergic
Neurotransmission
A polysomnographic study in children with refractory NE,
showed important sleep fragmentation with increased cortical
arousals associated with PLMS. This was confirmed in a case
control study and in a homogeneous group of children with
monosymptomatic NE and NP. In adults, a population-based
epidemiological study from Finland found a correlation
between nocturia and the presence of restless leg syndrome,
which is strongly associated with PLMS in adults. In all these
studies, patients had an increased presence of PLMS, which is
associated with impaired central dopaminergic
transmission.17,18,20
The dopaminergic projections from the hypothalamic A11
regions go to the dorsal (sensory) and ventral (motor) horn of
the spinal cord and to the intermediolateral nucleus of the
spinal gray matter, the final common output of the spinal
sympathetic system. An impairment of this descending control,
for example, in patients with dopamine depletion (Parkinson’s
disease and PLMS), may have two consequences: (i) a reduced
inhibitory modulation of the sensory/motor input; and (ii) an
increase in sympathetic output from the intermediolateral
nucleus, which might result in a sympathetic shift to a higher
level of activity with increasing systolic and diastolic blood
pressure.21
Animal studies further underline the possible role for
dopamine in the pathophysiology of nocturia. Sleep deprived
cats demonstrated a decrease in the amount of immunoreac-
tive tyrosine hydroxylase, the key enzyme in dopamine
synthesis, followed by an increased amount after sleep
deprivation. At a supraspinal level, dopamine D2 receptor
agonists, suppressed the activity of the sphincter muscle and
reduced the urethral pressure, while on the opposite, dopamine
D1 receptor agonists showed an inhibitory effect on the
micturition reflex. D1 receptor antagonists (or dopamine
depletion) demonstrated a facilitation of the micturition reflex,
while the impact of a D2 antagonist on the urethral sphincter
was negligible.22
In humans, previous studies indicated a correlation between
the presence of LUTS and a degeneration of dopaminergic
TABLE II. Comparison of the 24hr FVC, Nocturnal-Only FVC, and Nocturnal FVC With 24hr Volume








bladder capacity NBCI> 1.3
Decreased global bladder
capacity MVV< 200ml
Global polyuria 24hr urine
volume >3,000ml
24hr FVC 63.2 43.5 39.3 18.3 12.3
Nocturnal FVC 0.0 43.5 29.5 27.0 0.0
Nocturnal FVC with
24hr volume
63.2 43.5 29.5 27.0 12.3
FVC, frequency volume chart; MVV, mean voided volume; NBCI, nocturnal bladder capacity index; NPi, nocturnal polyuria index; NUP, nocturnal urine
production.
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neurons. In adults, a reduced inhibition ofmotor activity and an
increased sympathetic outputwas seen and correlatedwith the
degeneration of dopaminergic neurons in the striatal nigra.
Detrusoroveractivity in patients with Parkinson’s disease
seemed to be caused by a reduction in the dopamine D1
receptor stimulation. Moreover, in some Parkinson’s patients
treated with dopamine-D1-agonists, an increase in ADH
appeared.23,24
Sleep Fragmentation, Cortical Arousals, and Autonomic
Activation
Arousals are an integral component of the sleep process but
are also considered as a marker of sleep disruption. They
influence the electroencephalography and are often associated
with an increased sympathetic activity, reflected by an
increased heart rate and blood pressure or body movements.
There is evidence that interruption of sleep by arousals
diminishes its recuperative value, impairs sleep continuity,
and causes sleep deprivation.25
Acute sleep deprivation affects NUP by increasing sodium
andwater diuresis, and increases heart rate and blood pressure.
Interestingly, this non-dipping hypertension and NP are highly
prevalent in patients with nocturia. If we assume that sleep
fragmentation leads to sleep deprivation in patients with
nocturia, then this has an important effect on daytime
functioning, endocrine, metabolic, immune, inflammatory,
and cardiovascular regulation.14 The first nocturia episode
typically occurs after 2–3hr of sleep and interrupts the slow
wave sleep, which is a restorative phase of sleep with an
important role for cognitive and physiological processes, such
as glucose and insulin homeostasis. Therefore, the duration of
first uninterrupted sleep period is often a secondary endpoint in
pharmacological trials evaluating treatments for nocturia.16,26
Periodic Limb Movements and Circadian Rhythms
The circadian rhythm is a crucial component in sleep
physiology as well as in the regulation of many physiological
parameters such as sodium and water handling. A genetic risk
factor for PLMS was found in North European populations, and
this was recently confirmed by an American study concluding
that PLMS caused by dopamine depletion leads to dysregula-
tion of cellular iron storage and inactivation of critical enzymes
in dopaminergic neurons with consequent phenotypic effects
on sleep. Moreover, the affected protein possibly interacts
indirectly with the molecular mechanism in the central
hypothalamic region. So, the observations of PLMS in nocturia
might so far reflect a dopaminergic dysregulation with a
possible central circadian defect. Of course, further research has
to elucidate this hypothesis.27–29
REASONS FOR AWAKENING PRIOR TO NOCTURIA: RESULTS OF A
RETROSPECTIVE SURVEY STUDY
The extent to which the urge to urinate may be a
consequence, rather than a cause, of nocturnal awakenings
was assessed by asking individuals to report the reasons they
awakened during nocturia events.
Methods
A sample of 356 American women between the ages of 18
and 40 years was recruited from a panel of participants
maintained by an online survey organization such that about
one-third reported that they had been diagnosed by a physician
with overactive bladder (OAB) syndrome. Participants com-
pleted online questionnaires about demographic character-
istics, whether they needed assistance to go to the toilet,
frequency of nocturia, and OAB symptoms (OAB Symptom
Scale, OABSS). OAB was defined as an OABSS score >7.30
Subjects were also asked ‘‘When you wake up at night and
urinate, what is usually the reason for awakening?’’ They could
check asmany reasons as applied andwere given the following
options: noise, another person, dreams, urge to urinate, I do not
know, and other. Descriptive statistics were used to analyze the
data. Women who needed assistance to the toilet (n¼ 28) were
excluded from analysis.
Results
A total of 328 women, with a mean age of 30 years, were
included and divided into an OAB group (n¼199) and non-OAB
group (n¼129). The reasons for awakening in 255womenwho
reported any nocturia (91% in OAB group; 57% in non-OAB
group) are represented in Figure 1. Subjects who selected the
‘‘other’’ category (n¼ 2) were discarded from the analysis. Urge
to urinatewas themost prevalent reason for awakening in both
groups both for single (56%) and two or more events (83%).
However, reasons for awakening other than urinary urge were
reported by 17–29% of the respondents. Thirty one percent
(n¼ 78) of those with nocturia reported that it was not the urge
to urinate that awakened them, and among the 177 subjects
who reported the urge to urinate as a reason for awakening,
40% (n¼70) also reported other reasons. Thus 58% (n¼148) of
women with nocturia reported reasons for awakening other
than the urge to urinate.
Discussion
These findings indicate that 58% of women with nocturia
recognize that they are awakened for reasons other than the
urge to urinate. Nevertheless, these awakenings led to
nocturnal voids either as ‘‘convenience’’ voids or because the
urge to urinate occurred after awakening. The latter suggests
that the urge to urinate on awakening may be a Pavlovian or
psychological response rather than a physiological response.
People may be conditioned to get up to urinate when they
awaken and acquire the urge and the behavior of nocturnal
urination. These findings are consistent with a previous study
in an older sample, which showed that the number of daytime
cues subjects associated with the urge to urinate was
significantly associated with number of nocturia events.31
This study has limitations. First, the participants were all
computer users and female. Second, the findings on reasons for
nocturia events are based on retrospective self-reports and,
therefore, may be subject to reporting bias.
Fig. 1. Reasons for awakening for nocturia events in 255 women.
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Conclusion
These results suggest that Pavlovian processes may be a
factor in nocturia. In patients with nocturia due to conditioned
responses to awakenings, measures to decrease nocturnal
awakenings, such as pharmacological or behavioral sleep aids
could be useful in decreasing nocturia. Moreover, behavioral
strategies to prevent nocturia despite awakenings might be
instituted. These strategies might include pelvic floor exercises
or self-talk to encourage returning to sleep rather than arising
to urinate. Recommendations for future research about sleep,
nocturia and NP are summarized in Table I.
CONCLUSION
In order to optimize the management of nocturia and NP,
future research has to focus on the development of unambigu-
ous terminology regarding nocturia andNP, the role of RFPs and
simplified FVCs as guidance of individualized therapy and the
role of sleep disorders such as PLMS and habitual voiding as a
response to awakening.
REFERENCES
1. Abrams P, Cardozo L, FallM, et al. The standardisation of terminology of lower
urinary tract function: Report from the standardisation sub-committee of the
International Continence Society. Am J Obstet Gynecol 2002;187:116–26.
2. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of
terminology in nocturia: Report from the standardization subcommittee of
the International Continence Society. BJU Int 2002;90:11–5.
3. Weiss JP, van Kerrebroeck PE, Klein BM, et al. Excessive nocturnal urine
production is a major contributing factor to the etiology of nocturia. J Urol
2011;186:1358–63.
4. Goessaert AS, Krott L, Hoebeke P, et al. Diagnosing the pathophysiologic
mechanisms of nocturnal polyuria. Eur Urol 2015;67:283–8.
5. Welliver C, Sulaver R, Whittington A, et al. Analyzing why men seek
treatment for lower urinary tract symptoms and factors associatedwith non-
improvement. Urology 2015;86:862–7.
6. Bosch JL, Everaert K, Weiss JP, et al. Would a new definition and classification
of nocturia andnocturnal polyuria improve ourmanagement of patients? ICI-
RS 2014. Neurourol Urodyn 2016;35:283–7.
7. DrakeMJ,Mills IW,Nobe JG.Melatonin pharmacotherapy for nocturia inmen
with benign prostatic enlargement. J Urol 2004;171:1199–202.
8. Hofmeester I, Kollen BJ, Steffens MG, et al. The association between nocturia
and nocturnal polyuria in clinical and epidemiological studies: A systematic
review and meta-analyses. J Urol 2014;191:1028–33.
9. van Doorn B, Blanker MH, Kok ET, et al. Prevalence, incidence, and resolution
of nocturnal polyuria in a longitudinal community-based study in oldermen:
The Krimpen study. Eur Urol 2013;63:542–7.
10. Weiss JP, Bosch JL, Drake M, et al. Nocturia think tank: Focus on nocturnal
polyuria: ICI-RS 2011. Neurourol Urodyn 2012;31:330–9.
11. Goessaert A,Walle JV, Bosch JL, et al. Nocturnal Polyuria—Excess of nocturnal
urine production, excess of definitions: Influence on renal function profile.
J Urol 2016;195:670–6.
12. Ku JH, Jeong IG, Lim DJ, et al. Voiding diary for the evaluation of urinary
incontinence and lower urinary tract symptoms: Prospective assessment of
patient compliance and burden. Neurourol Urodyn 2004;23:331–5.
13. Burton C, Weiss JP, Parsons M, et al. Reference values for the Nocturnal
Bladder Capacity Index. Neurourol Urodyn 2011;30:52–7.
14. Czeisler C. Human circadian physiology: Internal organization of tempera-
ture, sleep-wake, and neuroendocrine rhythmsmonitored in an environment
free of time cues. Palo Alto: Stanford University; 1978.
15. Dijk D, Edgar D. Circadian and homeostatic control of wakefulness and sleep.
In: Turek FW, Zee PC, editors. Regulation of sleep and wakefulness. New York,
NY: Marcel Dekker Inc.; 1999. 111–47.
16. van Kerrebroeck P, Hashim H, Holm-Larsen T, et al. Thinking beyond the
bladder: Antidiuretic treatment of nocturia. Int J Clin Pract 2010;64:807–16.
17. Dhondt K, Baert E, Van Herzeele C, et al. Sleep fragmentation and increased
periodic limb movements are more common in children with nocturnal
enuresis. Acta Paediatr 2014;103:e268–72.
18. Dhondt K, Van Herzeele C, Roels SP, et al. Sleep fragmentation and periodic
limbmovements in childrenwithmonosymptomatic nocturnal enuresis and
polyuria. Pediatr Nephrol 2015;30:1157–62.
19. Hoshiyama F, Hirayama A, Tanaka M, et al. The impact of obstructive sleep
apnea syndrome on nocturnal urine production in older men with nocturia.
Urology 2014;84:892–6.
20. Tikkinen KA, Auvinen A, Johnson TM 2nd, et al. A systematic evaluation of
factors associated with nocturia—The population-based FINNO study. Am J
Epidemiol 2009;170:361–8.
21. Clemens S, Rye D, Hochman S. Restless legs syndrome: Revisiting the
dopamine hypothesis from the spinal cord perspective. Neurology
2006;67:125–30.
22. Yoshimura N, Miyazato M, Kitta T, et al. Central nervous targets for the
treatment of bladder dysfunction. Neurourol Urodyn 2014;33:59–66.
23. Arai M. Increased plasma arginine vasopressin levels in dopamine
agonist-treated Parkinson’s disease patients. Neuro Endocrinol Lett
2011;32:39–43.
24. Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine
transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal
dopaminergic function in Parkinson’s disease with urinary dysfunction.
J Neurol Sci 2001;187:55–9.
25. Halasz P, TerzanoM, Parrino L, et al. The nature of arousal in sleep. J Sleep Res
2004;13:1–23.
26. Tasali E, Leproult R, Ehrmann DA, et al. Slow-wave sleep and the risk of type 2
diabetes in humans. Proc Natl Acad Sci USA 2008;105:1044–9.
27. Freeman AA, Mandilaras K, Missirlis F, et al. An emerging role for Cullin-3
mediated ubiquitination in sleep and circadian rhythm: Insights from
Drosophila. Fly (Austin) 2013;7:39–43.
28. Moore Ht, Winkelmann J, Lin L, et al. Periodic legmovements during sleep are
associatedwith polymorphisms in BTBD9, TOX3/BC034767,MEIS1,MAP2K5/
SKOR1, and PTPRD. Sleep 2014;37:1535–42.
29. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb
movements in sleep. N Engl J Med 2007;357:639–47.
30. Blaivas JG, Panagopoulos G, Weiss JP, et al. Validation of the overactive
bladder symptom score. J Urol 2007;178:543–7.
31. Singer J, O’Connell K. An exploratory analysis of the role of cue-induced
urinary urges in nocturia. Clin Gerontol 2016;39:240–51.
2052 Denys et al.
Neurourology and Urodynamics DOI 10.1002/nau
